By Christine A. Wu, Senior Research Analyst, LSN
Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.
LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.
The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:
- Kelly Holman, Co-Founder and Managing Partner, Genesys Capital
- Inès Holzbaur, General Partner, AmorChem Financial
- David O’Neill, Vice President, Business Development, Fight Against Cancer Innovation Trust
- Nicola La Monica, Senior Director, Infectious Disease Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson
The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09
This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.